DE69321909D1 - Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden - Google Patents

Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden

Info

Publication number
DE69321909D1
DE69321909D1 DE69321909T DE69321909T DE69321909D1 DE 69321909 D1 DE69321909 D1 DE 69321909D1 DE 69321909 T DE69321909 T DE 69321909T DE 69321909 T DE69321909 T DE 69321909T DE 69321909 D1 DE69321909 D1 DE 69321909D1
Authority
DE
Germany
Prior art keywords
treatment
monoclonal antibodies
bacterial meningitis
tnf monoclonal
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69321909T
Other languages
English (en)
Other versions
DE69321909T2 (de
Inventor
Richard F Hector
Michael S Collins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of DE69321909D1 publication Critical patent/DE69321909D1/de
Application granted granted Critical
Publication of DE69321909T2 publication Critical patent/DE69321909T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69321909T 1992-08-28 1993-08-16 Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden Expired - Lifetime DE69321909T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93793992A 1992-08-28 1992-08-28

Publications (2)

Publication Number Publication Date
DE69321909D1 true DE69321909D1 (de) 1998-12-10
DE69321909T2 DE69321909T2 (de) 1999-04-01

Family

ID=25470604

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69321909T Expired - Lifetime DE69321909T2 (de) 1992-08-28 1993-08-16 Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden

Country Status (6)

Country Link
US (1) US5616321A (de)
EP (1) EP0585705B1 (de)
AT (1) ATE172880T1 (de)
DE (1) DE69321909T2 (de)
DK (1) DK0585705T3 (de)
ES (1) ES2121907T3 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE69427928T3 (de) † 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP3299393A1 (de) 2002-11-08 2018-03-28 Ablynx N.V. Gegen den tumornekrosefaktor-alpha gerichtete antikörper mit einfacher domäne und verwendungen dafür
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
JP4484664B2 (ja) * 2003-11-27 2010-06-16 キヤノン株式会社 記録ヘッドカートリッジ
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
PL1888641T3 (pl) 2005-05-18 2012-05-31 Ablynx Nv Białka wiążące albuminę surowicy
TWI392684B (zh) 2006-04-05 2013-04-11 Abbott Biotech Ltd 抗體之純化
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN103764824B (zh) 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
JP6134392B2 (ja) 2013-01-25 2017-05-24 サイモン・エルエルシー 循環している生物学的に活性な可溶性ｔｎｆの選択的低減用の組成物およびｔｎｆ媒介性疾患を処置する方法
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2803365A1 (de) 2013-05-14 2014-11-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Verwendung von Clonazepam in Verbindung mit Antibiotika bei der Behandlung von bakteriell verursachter Meningitis
EP3052640A2 (de) 2013-10-04 2016-08-10 AbbVie Inc. Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (de) 2015-04-10 2016-10-12 Ares Trading S.A. Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0288088B1 (de) * 1987-04-24 1994-03-09 Teijin Limited Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
AU626572B2 (en) * 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin
EP0355067A1 (de) * 1988-08-19 1990-02-21 Celltech Limited Arzneimittel gegen bösartige Gewebeneubildung
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
CA2090401A1 (en) * 1990-08-27 1992-02-28 Deborah A. Rathjen Method of treating viral infection
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
DE07012626T1 (de) * 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
DE69312077T2 (de) * 1992-10-08 1997-10-30 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
EP0732938A4 (de) * 1993-12-01 1997-03-19 Unisearch Ltd Verfahren zur behandlung von intestinalen störungen

Also Published As

Publication number Publication date
DK0585705T3 (da) 1999-07-26
DE69321909T2 (de) 1999-04-01
ATE172880T1 (de) 1998-11-15
US5616321A (en) 1997-04-01
ES2121907T3 (es) 1998-12-16
EP0585705A1 (de) 1994-03-09
EP0585705B1 (de) 1998-11-04

Similar Documents

Publication Publication Date Title
ATE172880T1 (de) Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden
DE68927671D1 (de) Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
ATE249518T1 (de) Humanisierter antikörper gegen cd18
ATE117434T1 (de) Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
GR3026750T3 (en) Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein.
DE69221501T2 (de) Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen
DE69733960D1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
ATE155043T1 (de) Behandlung von autoimmun- und entzundungskrankheiten
GB9125768D0 (en) Therapeutic method
DE69424915D1 (de) Verwendung von 1-2-4-Benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
DE68921979T2 (de) Antikörper für die antilymphozyten-antikörpertherapie.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
RU93004678A (ru) Противомикробные производные карбапенема, способы их получения и применение
DK0792162T3 (da) Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier
ATE28214T1 (de) Malolaktisches gaerungsverfahren.
NO934655L (no) Legemiddel for gram-positive sykdommer i akvatiske arter
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
DE59008759D1 (de) Verwendung von interleukin-2 zur behandlung der endotoxinämie.
ATE33842T1 (de) Immuninterferon und verfahren zu seiner reinigung.
EP0321094A3 (de) Behandlung von Faktor-VIII-Inhibitoren
DE68924963D1 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.
EA200101271A1 (ru) Блокирующее моноклональное антитело к vla-1 и его применение для лечения воспалительных заболеваний
TR199700791T1 (xx) Kendiliğinden bağışıklığı olan hastalıkların ve allograft rejeksiyonun tedavisi için LCK SH2 spesifik bileşimlerinin kullanılması.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition